可可英语晨读，每天有进步！查看每期晨读完整版中英双语全文，微信关注“可可英语晨读”公众号。更多更快更精彩的内容，尽在“可可英语晨读”公众号。

Pill for Covid does not reduce risk of hospitalisation or death, UK study finds

An oral antiviral pill for Covid speeds up recovery among vaccinated yet vulnerable patients, but does not reduce their likelihood of needing hospital care or dying, research has suggested.

The UK became the first country in the world in November 2021 to approve molnupiravir for Covid, and the pill can be taken twice a day at home.

At the time hopes were high after a study suggested that the antiviral halved the risk of hospitalisation or death among unvaccinated high-risk patients. But shortly after approval was given, further work, conducted when the Delta variant dominated, suggested the drug had a smaller effect than first thought.

Now research published in the Lancet has found molnupiravir does not reduce the risk of hospitalisation or death in vaccinated, high-risk people faced with the Omicron variant.

可可英语晨读，每天有进步！查看每期晨读完整版中英双语全文，微信关注“可可英语晨读”公众号。更多更快更精彩的内容，尽在“可可英语晨读”公众号。